Idience, a subsidiary of Ildong Pharmaceutical, has acquired IDX-1197, an immunotherapy drug, as its first pipeline.
The introduction of the new pipeline came four months after Ildong Pharmaceutical established Idience as a no research and development only (NRDO) company in May.
With the acquisition, Idience has decided to launch phase 1b and 2a clinical trial for the drug this year, which will target more cancers than the previous 1a trials conducted by Ildong.
The company has also acquired patents for IDX-1197 in the U.S., Canada, Russia, Japan, Singapore and Australia, and plans to pursue various commercialization strategies such as drug development and licensing agreements depending on the progress of the drug’s research and development.
IDX-1197, discovered by Ildong Pharmaceutical, inhibits the action of the enzyme PARP (Poly ADP-ribose polymerase), which treats DNA damage in tumor cells to kill cancer.